Amedisys Inc. (NASDAQ:AMED) saw a significant increase in short interest in September. As of September 15th, there was short interest totalling 2,803,524 shares, an increase of 148.5% from the August 31st total of 1,128,093 shares. Currently, 8.6% of the shares of the company are sold short. Based on an average trading volume of 187,976 shares, the short-interest ratio is currently 14.9 days.
Several equities analysts have recently issued reports on AMED shares. Stephens started coverage on Amedisys in a report on Thursday, June 16th. They issued an “equal weight” rating and a $55.00 target price for the company. Zacks Investment Research raised Amedisys from a “hold” rating to a “buy” rating and set a $57.00 target price for the company in a report on Tuesday, July 5th. Mizuho lowered Amedisys from a “buy” rating to a “neutral” rating and reduced their target price for the company from $57.00 to $55.00 in a report on Wednesday, August 3rd. Jefferies Group reaffirmed a “buy” rating on shares of Amedisys in a report on Tuesday, September 6th. Finally, Wells Fargo & Co. reaffirmed a “buy” rating on shares of Amedisys in a report on Sunday, September 11th. Seven research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $51.75.
Several institutional investors have recently added to or reduced their stakes in AMED. Norges Bank acquired a new position in Amedisys during the fourth quarter valued at about $13,561,000. Aperio Group LLC raised its position in shares of Amedisys by 9.4% in the first quarter. Aperio Group LLC now owns 15,934 shares of the company’s stock worth $770,000 after buying an additional 1,363 shares during the last quarter. Nisa Investment Advisors L.L.C. purchased a new position in shares of Amedisys during the first quarter worth $846,000. Prudential Financial Inc. raised its position in shares of Amedisys by 2.8% in the first quarter. Prudential Financial Inc. now owns 75,959 shares of the company’s stock worth $3,672,000 after buying an additional 2,100 shares during the last quarter. Finally, Algert Global LLC raised its position in shares of Amedisys by 32.1% in the first quarter. Algert Global LLC now owns 12,975 shares of the company’s stock worth $627,000 after buying an additional 3,155 shares during the last quarter. Hedge funds and other institutional investors own 91.45% of the company’s stock.
Amedisys (NASDAQ:AMED) opened at 47.44 on Friday. The company has a market capitalization of $1.59 billion, a price-to-earnings ratio of 41.50 and a beta of 1.05. Amedisys has a one year low of $31.16 and a one year high of $55.16. The firm’s 50-day moving average price is $48.27 and its 200 day moving average price is $49.66.
Amedisys (NASDAQ:AMED) last released its earnings results on Tuesday, August 2nd. The company reported $0.42 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.42. Amedisys had a net margin of 2.78% and a return on equity of 12.17%. The firm earned $360 million during the quarter, compared to analyst estimates of $353.07 million. During the same period last year, the business earned $0.43 earnings per share. The business’s revenue was up 14.8% on a year-over-year basis. On average, equities research analysts expect that Amedisys will post $1.69 earnings per share for the current fiscal year.
Amedisys, Inc (Amedisys) is a provider of home health and hospice services. The Company offers home health services to the chronic, co-morbid, aging American population. The Company operates through three segments: home health, hospice and personal care. The Company’s home health segment delivers a range of services in the homes of individuals recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important personal tasks.
Receive News & Ratings for Amedisys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc. and related companies with MarketBeat.com's FREE daily email newsletter.